During a live event, Thomas G. Martin, MD, discussed updated findings from the CARTITUDE-1 trial of cilta-cel and what they signify for patients with no disease progression at 5 years.

The discovery of new cancer cells with a switched-on gene called ZBTB16 is a breakthrough in childhood blood cancer research.

Artiva remains on track to share initial clinical response data and conduct U.S. Food and Drug Administration (FDA) regulatory interactions to align on pivotal trial design for AlloNK in refractory ...

Under the floodlights near Munich Airport, Audi turned a hangar into a Formula 1 launchpad. The R26 Concept rolled out of the ...

A new study from the Icahn School of Medicine at Mount Sinai helps explain why some people with multiple myeloma, a type of ...

The treatment landscape for systemic lupus erythematosus (SLE) has shifted greatly in recent years, driven by the emergence of cell-based immunotherapies targeting pathogenic B-cell populations. Among ...

New research suggests that DNA variants help predict toxicity and response in CAR T-cell therapy for large B-cell lymphoma.

Johnson & Johnson and Legend Biotech are said to have withdrawn an abstract originally planned for next month’s Amer | “At this point, the abstract was withdrawn in alignment with the authors, and we ...

Audi has outlined its ambition to fight for the Formula 1 World Championship by 2030 at the unveiling of a concept car in ...